Compare · ALBT vs ARGX
ALBT vs ARGX
Side-by-side comparison of Avalon GloboCare Corp. (ALBT) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALBT and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 12677.2x ALBT ($4.2M).
- Over the past year, ALBT is down 86.4% and ARGX is up 52.5% - ARGX leads by 138.9 points.
- ALBT has been more active in the news (10 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for ALBT).
- Company
- Avalon GloboCare Corp.
- argenx SE
- Price
- $0.29-4.97%
- $861.30+0.30%
- Market cap
- $4.2M
- $53.41B
- 1M return
- -10.24%
- -1.91%
- 1Y return
- -86.43%
- +52.49%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 10
- 3
- Recent ratings
- 0
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ALBT
- Avalon GloboCare Expands AI Product Portfolio with Planned Launch of Beacon, an Agentic Generative Engine Optimization Platform for Small Businesses
- SEC Form DEL AM filed by Avalon GloboCare Corp.
- SEC Form 4 filed by Director Lu Wenzhao
- SEC Form 4 filed by Director Sanders Steven Andrew
- SEC Form 4 filed by Director Mathews Michael
- SEC Form 4 filed by Interim CEO Li Meng
- SEC Form 4 filed by Chief Strategy Officer Ingargiola Luisa
- SEC Form 4 filed by Director Felix Lourdes
- SEC Form S-1 filed by Avalon GloboCare Corp.
- Avalon GloboCare Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG